Severe Community Acquired Pneumonia clinical trials

Explore recruiting severe community acquired pneumonia clinical trials.

Recruiting severe community acquired pneumonia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Severe Community Acquired Pneumonia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Exploratory, Multi-Centre, Interventional, Prospective, Randomised, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of AON-D21 in Patients with Severe Community-Acquired Pneumonia.

Belgium, France, Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

STRAtified Dosing based on Augmented renal clearance for CEFtriaxone in patients with severe community-acquired pneumonia: the STRADA-CEF trial

Belgium

Therapeutic use (Phase IV) EU CTIS Study details

CUSTOMIZED ANTIBIOTIC TREATMENT DURATION AMONG HOSPITALIZED PATIENTS WITH MODERATELY SEVERE COMMUNITY-ACQUIRED PNEUMONIA [CAT-CAP]

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Aspirin to prevent cardiovascular events in patients with community-acquired pneumonia or influenza

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with severe community-acquired pneumonia (sCAP)

Romania, Ireland, Germany, Spain, Belgium, Austria +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with CAP including COVID-19 pneumonia.

Belgium, Austria, Slovakia, Germany, Lithuania, Hungary +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Severe Community Acquired Pneumonia trials by city

Severe Community Acquired Pneumonia in Toronto Severe Community Acquired Pneumonia in Vancouver Severe Community Acquired Pneumonia in Montreal Severe Community Acquired Pneumonia in Calgary Severe Community Acquired Pneumonia in Edmonton Severe Community Acquired Pneumonia in Ottawa Severe Community Acquired Pneumonia in Winnipeg Severe Community Acquired Pneumonia in Quebec City Severe Community Acquired Pneumonia in Hamilton Severe Community Acquired Pneumonia in Kitchener Severe Community Acquired Pneumonia in London Severe Community Acquired Pneumonia in Halifax Severe Community Acquired Pneumonia in New York Severe Community Acquired Pneumonia in Los Angeles Severe Community Acquired Pneumonia in Chicago Severe Community Acquired Pneumonia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease